<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4539">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778059</url>
  </required_header>
  <id_info>
    <org_study_id>USB002-2020-001</org_study_id>
    <nct_id>NCT04778059</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19</brief_title>
  <official_title>Phase 2 Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravenous USB002 to Treat Patients With Respiratory Distress Due to COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Biotest, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>US Biotest, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study the use of USB002 given as an intravenous infusion in patients with&#xD;
      respiratory distress due to infection with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment emergent adverse events (TEAE)</measure>
    <time_frame>Day 1 to Day 70 (or date of final measurement, if sooner)</time_frame>
    <description>Treatment emergent adverse events (including changes in laboratory assessments, physical examination findings, and vital signs)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>2019 Novel Coronavirus Infection</condition>
  <condition>COVID-19 Virus Infection</condition>
  <condition>SARS Coronavirus 2 Infection</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <condition>Adult Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>USB002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>USB002</intervention_name>
    <description>USB002 is pharmaceutically formulated Angiotensin 1-7 [A(1-7)], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002. Depending upon cohort assignment, subjects in the USB002 group will receive one of four doses of USB002 administered intravenously (IV).</description>
    <arm_group_label>USB002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo formulation will be the USB002 formulated solution without the addition of A(1-7). The placebo will be administered intravenously (IV).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent from patient or legal representative;&#xD;
&#xD;
          2. Age 18 or greater;&#xD;
&#xD;
          3. Positive reverse transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 (&lt;10&#xD;
             days);&#xD;
&#xD;
          4. Respiratory rate &gt; 20 RR;&#xD;
&#xD;
          5. SpO2 &lt; 92% on room air, requiring supplemental oxygen, requiring invasive mechanical&#xD;
             ventilation, or requiring ECMO;&#xD;
&#xD;
          6. Chest X-ray confirming bilateral pulmonary infiltrates;&#xD;
&#xD;
          7. Body mass index of &lt; 40 units/kg/m2;&#xD;
&#xD;
          8. Adequate method of birth control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Terminally ill patients due to underlying cardiac, cancer or severe debilitating&#xD;
             neurological disease including coma;&#xD;
&#xD;
          2. Hospitalization expected to be &lt; 96 hours due to medical improvement;&#xD;
&#xD;
          3. Interstitial lung disease;&#xD;
&#xD;
          4. Correction of QTc values obtained by 12 lead EKG using Fredericia's formula (QTcF) &gt;&#xD;
             450 ms;&#xD;
&#xD;
          5. History of hypotension (mean arterial blood pressure &lt; 65 mmHg), unrelated to CoVID-19&#xD;
             infection;&#xD;
&#xD;
          6. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3 times upper&#xD;
             limit of normal;&#xD;
&#xD;
          7. Participating concurrently on another clinical trial for the experimental treatment of&#xD;
             COVID-19;&#xD;
&#xD;
          8. Active chemotherapy use;&#xD;
&#xD;
          9. Pregnant and/or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sairam Parthasarathy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Arizona Health Sciences Center/ Banner Healthcare Systems Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gere diZerega, MD</last_name>
    <phone>805-595-1300</phone>
    <email>gere.dizerega@usbiotest.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shelagh Verco, PhD</last_name>
    <phone>805-704-1179</phone>
    <email>shelagh.verco@usbiotest.com</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

